This ASX 200 share has 'all the qualities of a compounder': experts

The Pro Medicus Limited share price may be trading on a P/E ratio of 105 but these two experts say it's a buy today.

| More on:
Person pointing at an increasing blue graph which represents a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Pro Medicus share price may be trading on a P/E ratio of 105 but these two experts say it's a buy 
  • Hayborough Investment Partners' Ben Rundle says the business has "all the qualities of a compounder"  
  • Medallion Financial's Michael Wayne says revenue, earnings, margins, and return on equity (ROE) are "trending in the right direction" 

The Pro Medicus Limited (ASX: PME) share price is up 1% to $51.83 at the time of writing.

The ASX healthcare share got a bit of a plug from two analysts today. Let's see what Hayborough Investment Partners' Ben Rundle and Medallion Financial's Michael Wayne had to say.

Pro Medicus share price a buy: experts

In a Livewire interview, Rundle said the ASX 200 darling is a buy despite its eye-watering valuation.

Westpac data shows the Pro Medicus share price is trading on a price-to-earnings (P/E) ratio of 105.18.

That's almost five times the healthcare sector of 21.83 and seven times the broader market P/E of 14.79.

In its FY22 full-year results released in August, Pro Medicus reported a net profit of $44.4 million, up 44.1% on FY21, and no debt.

Rundle said:

Look, I recognise that it's on an eye-watering valuation, but it's just such a high-quality business. The quality of its earnings is fantastic, it has a fantastic management team, and a great product.

It's really hard to bet against this company. It has all the qualities of a compounder, and therefore I think it keeps compounding.

Wayne added his buy endorsement, too:

It's one that we've held for some time and continue to like it. You look at the balance sheet, all those key metrics are trending in the right direction — revenue, earnings, margins, and return on equity (ROE).

They developed a very good product, and have been able to go out and market it very well and win very high-quality contracts. A lot of their contracts are six to eight years. A lot of those have been renewed and rolled over.

They've also got a good backlog of inquiries for different tenders.

What's next for Pro Medicus?

Wayne said he was keeping an eye on the expansion of Pro Medicus and the take-up of its product.

He explained:

One concern that we might have just to be careful of long term is they've targeted the academic hospitals in the US (private academic hospitals). They've been very successful there. A lot of those hospitals aren't as cost-conscious as some of the others, so they might struggle to have as much of an impact on the broader hospital network in the US.

However, it's a proven product. It's very, very technologically advanced and can save a lot of time within those hospital operations.

Pro Medicus announced yesterday that it will hold its annual general meeting on 21 November.

Motley Fool contributor Bronwyn Allen has positions in Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus Ltd. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »